Index
-
Market Cap
3.82B
Enterprise Value
4.81B
Income
177.04M
Sales
3.40B
Book/sh
9.71
Cash/sh
13.01
Employees
3309
IPO
May 05, 2005
P/E
23.68
Forward P/E
12.18
PEG
0.65
P/S
1.13
P/B
4.03
P/C
3.01
P/FCF
6.02
EV/EBITDA
12.32
EV/Sales
1.42
Quick Ratio
2.50
Current Ratio
2.50
Debt/Eq
2.28
LT Debt/Eq
2.28
Option/Short
Yes / Yes
EPS (ttm)
1.65
EPS next Y
3.21
EPS next Q
0.25
EPS this Y
-49.61%
EPS next Y
161.31%
EPS next 5Y
18.87%
EPS past 3/5Y
-12.28% -8.51%
Sales past 3/5Y
2.82% 3.45%
EPS Y/Y TTM
-35.87%
Sales Y/Y TTM
8.86%
EPS Q/Q
-59.99%
Sales Q/Q
9.15%
Insider Own
0.92%
Insider Trans
-12.21%
Inst Own
103.93%
Inst Trans
8.64%
ROA
3.86%
ROE
19.78%
ROIC
5.69%
Gross Margin
94.78%
Oper. Margin
10.59%
Profit Margin
5.21%
SMA20
5.67%
SMA50
1.34%
SMA200
-11.38%
Trades
Shs Outstand
97.66M
Shs Float
96.77M
52W High
58.75 -33.38%
52W Low
34.13 14.67%
Volatility
3.59% 4.24%
ATR (14)
1.64
RSI (14)
58.19
Beta
1.45
Rel Volume
0.44
Avg Volume
1.67M
Volume
680,556
Perf Week
3.81%
Perf Month
8.51%
Perf Quarter
-10.52%
Perf Half Y
-10.56%
Perf YTD
-19.40%
Perf Year
-19.80%
Perf 3Y
38.89%
Perf 5Y
-18.29%
Perf 10Y
12.00%
Prev Close
38.35
Price
39.14
Change %
2.05%
Analysts 8 incl. previous ratings
Rating Distribution 1 Buy · 5 Hold · 2 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Apr 08, 2026 Downgrade K Keefe Bruyette
Outperform → Mkt Perform $47 +20.1% Jan 26, 2026 Initiated B BofA Securities
Buy $65 +66.1% Dec 11, 2025 Resumed U UBS
Neutral $54 +38.0% Oct 03, 2025 Initiated B BMO Capital Markets
Market Perform $56 +43.1% Aug 25, 2025 Upgrade K Keefe Bruyette
Mkt Perform → Outperform $65 +66.1% Apr 07, 2025 Downgrade M Morgan Stanley
Equal-Weight → Underweight $56 → $33 -15.7% Jan 03, 2025 Downgrade W Wolfe Research
Outperform → Peer Perform Dec 20, 2024 Downgrade K Keefe Bruyette
Outperform → Mkt Perform $65 → $57 +45.6% Dec 09, 2024 Downgrade M Morgan Stanley
Overweight → Equal-Weight $60 → $63 +61.0% Sep 12, 2024 Initiated W Wells Fargo
Equal Weight $51 +30.3% Jan 29, 2024 Resumed K Keefe Bruyette
Outperform $51 +30.3% Jan 03, 2024 Upgrade W Wolfe Research
Peer Perform → Outperform $42 +7.3% Sep 19, 2023 Downgrade G Goldman
Neutral → Sell $37 → $32 -18.2% Jul 13, 2023 Upgrade K Keefe Bruyette
Underperform → Mkt Perform $31 → $36 -8.0% Jul 12, 2023 Upgrade M Morgan Stanley
Equal-Weight → Overweight $36 → $43 +9.9% Jul 03, 2023 Upgrade W Wolfe Research
Underperform → Peer Perform Apr 12, 2023 Upgrade M Morgan Stanley
Underweight → Equal-Weight $29 → $36 -8.0% Jul 18, 2022 Downgrade M Morgan Stanley
Equal-Weight → Underweight $40 → $30 -23.3% Jul 13, 2022 Downgrade K Keefe Bruyette
Mkt Perform → Underperform $38 → $30 -23.3% Apr 07, 2022 Downgrade W Wolfe Research
Peer Perform → Underperform $39 -0.4%
Show Previous Ratings
Today 01:00AM
Oct-22-26 04:05PM
09:33AM
06:40AM
06:30AM
04:15PM
Loading…
Oct-21-26 04:15PM
Oct-20-26 08:00AM
Oct-19-26 09:04AM
03:00AM
Oct-12-26 06:45AM
Oct-01-26 08:00AM
Sep-28-26 08:00AM
Sep-22-26 04:15PM
Sep-21-26 09:11AM
08:00AM
12:46PM
Loading…
Sep-18-26 12:46PM
Sep-11-26 06:45AM
Sep-10-26 07:01AM
Aug-21-26 05:15PM
Aug-17-26 02:00AM
Aug-12-26 06:45AM
Aug-03-26 07:11AM
Jul-28-26 06:25AM
Jul-27-26 09:00AM
Jul-24-26 07:56AM
(Private Banker International)
01:13AM
Jul-23-26 03:01PM
09:43AM
(The Wall Street Journal)
08:36AM
(The Wall Street Journal)
06:43AM
06:30AM
Loading…
06:30AM
Jul-22-26 04:15PM
04:15PM
Jul-21-26 09:31AM
Jul-20-26 05:55AM
Jul-17-26 07:40AM
Jul-16-26 09:33AM
02:38AM
Jul-13-26 11:00AM
08:49AM
07:29AM
07:00AM
07:00AM
06:45AM
Jul-11-26 07:00AM
Jul-07-26 08:30AM
Jul-02-26 08:00AM
Jun-30-26 04:26AM
(Pharmaceutical Technology)
Jun-23-26 04:15PM
Jun-15-26 04:25PM
Jun-10-26 06:45AM
Jun-05-26 07:25PM
May-22-26 04:15PM
08:00AM
May-20-26 01:42PM
May-12-26 06:45AM
May-11-26 08:30AM
May-04-26 07:45AM
May-02-26 03:00AM
May-01-26 06:30AM
Apr-30-26 04:15PM
12:30AM
Apr-24-26 01:45AM
Apr-22-26 04:15PM
Apr-15-26 07:00AM
Apr-14-26 11:30AM
08:00AM
Apr-13-26 06:45AM
Mar-24-26 06:30PM
Mar-23-26 05:52PM
04:15PM
Mar-10-26 04:14PM
06:45AM
Mar-09-26 12:49PM
Mar-05-26 12:37PM
Mar-03-26 03:05PM
Feb-27-26 02:55PM
08:48AM
(The Wall Street Journal)
03:28AM
(The Wall Street Journal)
Feb-23-26 05:07PM
Feb-18-26 12:32PM
07:30AM
Feb-13-26 01:20PM
Feb-11-26 11:38PM
Feb-10-26 06:45AM
Feb-09-26 01:21PM
Feb-08-26 11:01PM
Feb-06-26 11:07AM
(Private Banker International)
Feb-05-26 07:25AM
12:44AM
Feb-04-26 08:40AM
Feb-03-26 05:15PM
Jan-30-26 01:09PM
12:30PM
12:33AM
Jan-29-26 11:41PM
07:45AM
07:17AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Andrew Alper Former Board Member Sep 01 '26 Proposed Sale 42.32 10,000 423,200 Sep 01 05:11 PM Orszag Peter Richard CEO & Chairman Aug 25 '26 Sale 43.52 125,000 5,440,038 260,942 Aug 26 08:51 PM Orszag Peter Richard Officer Aug 25 '26 Proposed Sale 43.52 125,000 5,440,043 Aug 25 04:29 PM Andrew Alper Former Board Member Aug 20 '26 Proposed Sale 42.77 10,000 427,700 Aug 20 06:07 PM Betsch Mary Ann Officer Apr 14 '26 Proposed Sale 49.85 9,092 453,221 Apr 14 04:12 PM Betsch Mary Ann Officer Apr 09 '26 Proposed Sale 45.00 3,030 136,350 Apr 09 01:09 PM Betsch Mary Ann Officer Apr 08 '26 Proposed Sale 45.00 3,030 136,350 Apr 08 04:37 PM Hogbin Christopher CEO Asset Management Mar 18 '26 Sale 40.37 7,885 318,317 15,773 Mar 19 07:37 PM Hogbin Christopher CEO Asset Management Mar 19 '26 Sale 39.37 3,944 155,275 11,829 Mar 19 07:37 PM Hogbin Christopher Officer Mar 19 '26 Proposed Sale 39.37 3,944 155,275 Mar 19 11:48 AM Betsch Mary Ann Former Officer Mar 19 '26 Proposed Sale 39.37 1,515 59,646 Mar 19 10:24 AM Orszag Peter Richard CEO & Chairman Mar 17 '26 Sale 40.76 69,170 2,819,274 210,942 Mar 18 05:58 PM Betsch Mary Ann Officer Mar 18 '26 Proposed Sale 40.37 1,515 61,161 Mar 18 10:56 AM Hogbin Christopher Officer Mar 18 '26 Proposed Sale 40.37 7,885 318,317 Mar 18 10:14 AM Betsch Mary Ann Officer Mar 17 '26 Proposed Sale 40.93 12,121 496,113 Mar 17 11:50 AM Orszag Peter Richard Officer Mar 17 '26 Proposed Sale 40.40 69,170 2,794,468 Mar 17 10:59 AM
Lazard, Inc. is a financial advisory and asset management firm, which engages in the provision of crafting solutions to the clients, including corporations, governments, institutions, partnerships, and individuals. It operates through the Financial Advisory and Asset Management segments. The Financial Advisory segment offers corporate, partnership, institutional, government, sovereign, and individual clients, an array of financial advisory services regarding mergers and acquisitions, restructurings, capital structure, capital raising, and corporate preparedness. The Asset Management segment provides global investment solutions and investment management services. The company was founded by Alexandre Lazard, Lazare Lazard, and Simon Lazard in 1848 and is headquartered in New York, NY.
CEO & Chairman Mr. Peter R. Orszag
Chief Operating Officer Ms. Alexandra Soto
General Counsel Mr. Christian A. Weideman
Chief Executive Officer of Lazard Asset Management LLC Mr. Christopher Edward Geroge Hogbin
President & Co-Head of Financial Advisory in North America Mr. Raymond J. McGuire